Search clinical trials for: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

Total 511 results

Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Chiesi Farmaceutici S.p.A.

Completed

Functional Respiratory Imaging Study (FRI) (FRI)

Chronic Obstructive Pulmonary Disease

Belgium, Hungary
Chiesi Farmaceutici S.p.A.

Active, not recruiting

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (FORCE2)

Asthma

United States
Chiesi Farmaceutici S.p.A.

Terminated

Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients (STORM)

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

Chronic Obstructive Pulmonary Disease | Asthma
Hull University Teaching Hospitals NHS Trust
Chiesi Farmaceutici S.p.A.

Completed

Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
PARZIBUT Gilles

Not yet recruiting

Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care (TRIMICU)

COPD Exacerbation
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Chiesi Farmaceutici S.p.A.

Completed

Functional Respiratory Imaging Study (DARWiIN)

Chronic Obstructive Pulmonary Disease

Belgium, Hungary
Pearl Therapeutics, Inc.

Completed

PK Study of PT003 and PT001 in Japanese Healthy Subjects

COPD

United States
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management (QvarAsthma)

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

Bronchial Asthma

Austria, Poland, Ukraine
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
UPECLIN HC FM Botucatu Unesp
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 (TRIVID)

Covid19

Brazil
Alfredo Antonio Chetta
University of Parma

Completed

The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and SAD in COPD Patients.

Chronic Obstructive Pulmonary Disease

Italy
The First Affiliated Hospital of Guangzhou Medical...
Guangdong Provincial Hospital of Traditional Chinese Medicine; Tongji Hospital and other collaborators

Not yet recruiting

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (CC-ICS)

Cough

China
Chiesi Farmaceutici S.p.A.

Completed

Triple in Asthma Dose Finding (Triskel)

Asthma

Bulgaria, Germany, Hungary, Italy, Poland, United Kingdom
Chiesi Farmaceutici S.p.A.

Withdrawn

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

COPD
Chiesi Farmaceutici S.p.A.

Completed

EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI

Bronchial Asthma

Poland, Ukraine
Zhujiang Hospital

Unknown

Small Airways Evaluation and Treatment

Pulmonary Disease，Chronic Obstructive;

China
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Chiesi Farmaceutici S.p.A.

Completed

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Childhood Asthma

Denmark
University Hospital, Antwerp
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients

Asthma

Belgium
AstraZeneca
Parexel

Completed

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Chronic Obstructive Pulmonary Disease - COPD

United States
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
Chiesi Farmaceutici S.p.A.

Completed

Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children (PAED2/FRESH)

Asthma

Spain, France, Romania, Bulgaria, Germany, Hungary, Italy, Poland, Russian Federation, Slovakia, Ukraine
Dey

Completed

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
SOFAR S.p.A.

Completed

Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

Italy
AstraZeneca
Parexel

Completed

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA

Chronic Obstructive Pulmonary Disease

United States
Chiesi Farmaceutici S.p.A.

Completed

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Chiesi SA/NV

Completed

Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting (TRIVOLVE)

Chronic Obstructive Pulmonary Disease

Belgium
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Asthma

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

Pharmacokinetics

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

Asthma
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

Asthma
University of Dundee
Teva Pharmaceuticals USA

Completed

Targeted Small Airways Therapy in Persistent Asthma (ANDA3)

Asthma

United Kingdom
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

Asthma
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Asthma

United States, Canada
Chiesi SAS
Kappa Santé

Recruiting

Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study (TriNEXT)

COPD

France
Chiesi Farmaceutici S.p.A.

Completed

Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children (PAED3)

Asthma

Poland, Ukraine
Chiesi Farmaceutici S.p.A.

Recruiting

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON)

COPD | COPD Exacerbation

United States, Bulgaria, Hungary, Poland, Argentina, Czechia, Mexico, Canada, Puerto Rico, Romania
GlaxoSmithKline

Completed

Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream

Psoriasis | Eczema | Itch | Allergy Symptoms
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.; i3 Research

Completed

Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study (USQvarAsthma)

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old (PAED1)

Asthma

Denmark
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Qvar vs FP in Pediatrics

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

Chronic Obstructive Pulmonary Disease

Hungary

3

Subscribe